Pharmaceutical giant Regeneron has emerged as the winning bidder for consumer genetics company 23andMe in a court-supervised bankruptcy sale, securing control of a vast database containing the genetic information of over 15 million individuals.

Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA data.

What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.